The American Society of Hematology has highlighted the need for the training of physicians and scientists, basic and clinical research, in hematology. The training program in hematology at the University of Minnesota addresses this concern by providing: 1) inter- and multi-disciplinary research training in five major realms of hematology;2 senior and junior faculty members of both genders as mentors;3) a fusion of research and clinical training for physician and PhD trainees;4) an outstanding resource-filled environment;and 5) the skills for trainees to both survive and thrive in academic medicine. The overarching objective of the training program is to train physicians and scientists for careers in academic medicine and hematology related research. Our program philosophy is to achieve this by carefully balancing sufficient structure to ensure rigor of the trainee experience and programmatic flexibility to accommodate the different needs of trainees. It is our intention to provide trainees with the basic skills that are adaptable to new paradigms of disease, capable of embracing of new technologies, and committed to the highest ethical standards. This post-doctoral training program will allow six trainees at least two years of research experience. This hematology training program, in the tradition of the last 35 years, is confident that future leader of hematology research will matriculate through the University of Minnesota program.
Advanced research training of doctors and scientists focused on blood diseases is essential to finding cures for leukemia or the prevention of fatal blood clots. This training program will prepare hematologists and scientists to develop new scientifically-based treatments and understandings of these diseases to improve the health and safety of patients will blood diseases.
|Osborn, Mark J; Webber, Beau R; McElmurry, Ronald T et al. (2017) Angiotensin receptor blockade mediated amelioration of mucopolysaccharidosis type I cardiac and craniofacial pathology. J Inherit Metab Dis 40:281-289|
|Pomeroy, E J; Lee, L A; Lee, R D W et al. (2017) Ras oncogene-independent activation of RALB signaling is a targetable mechanism of escape from NRAS(V12) oncogene addiction in acute myeloid leukemia. Oncogene 36:3263-3273|
|Angelos, Mathew G; Ruh, Paige N; Webber, Beau R et al. (2017) Aryl hydrocarbon receptor inhibition promotes hematolymphoid development from human pluripotent stem cells. Blood 129:3428-3439|
|Webber, Beau R; O'Connor, Kyle T; McElmurry, Ron T et al. (2017) Rapid generation of Col7a1-/- mouse model of recessive dystrophic epidermolysis bullosa and partial rescue via immunosuppressive dermal mesenchymal stem cells. Lab Invest 97:1218-1224|
|Skvarova Kramarzova, Karolina; Osborn, Mark J; Webber, Beau R et al. (2017) CRISPR/Cas9-Mediated Correction of the FANCD1 Gene in Primary Patient Cells. Int J Mol Sci 18:|
|Kramer, Ashley C; Blake, Amanda L; Taisto, Mandy E et al. (2017) Dermatopontin in Bone Marrow Extracellular Matrix Regulates Adherence but Is Dispensable for Murine Hematopoietic Cell Maintenance. Stem Cell Reports 9:770-778|
|Bastian, T W; Duck, K A; Michalopoulos, G C et al. (2017) Eltrombopag, a thrombopoietin mimetic, crosses the blood-brain barrier and impairs iron-dependent hippocampal neuron dendrite development. J Thromb Haemost 15:565-574|
|Dourado, Keina M C; Baik, June; Oliveira, Vanessa K P et al. (2017) Endoglin: a novel target for therapeutic intervention in acute leukemias revealed in xenograft mouse models. Blood 129:2526-2536|
|Davis, Zachary B; Vallera, Daniel A; Miller, Jeffrey S et al. (2017) Natural killer cells unleashed: Checkpoint receptor blockade and BiKE/TriKE utilization in NK-mediated anti-tumor immunotherapy. Semin Immunol 31:64-75|
|Eckfeldt, Craig E; Pomeroy, Emily J; Lee, Robin D W et al. (2016) RALB provides critical survival signals downstream of Ras in acute myeloid leukemia. Oncotarget 7:65147-65156|
Showing the most recent 10 out of 95 publications